These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23223539)

  • 21. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
    Gasperini C; Ruggieri S
    Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fingolimod treatment in multiple sclerosis].
    Tanaka M
    Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.
    Agius M; Meng X; Chin P; Grinspan A; Hashmonay R
    CNS Neurosci Ther; 2014 May; 20(5):446-51. PubMed ID: 24684973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of fingolimod.
    David OJ; Kovarik JM; Schmouder RL
    Clin Pharmacokinet; 2012 Jan; 51(1):15-28. PubMed ID: 22149256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod.
    d'Ambrosio A; Capuano R; Rossi S; Bisecco A; Lanza M; Gesualdo C; Leocani L; Rodegher M; Filippi M; Marino C; Maimone D; Tedeschi G; Simonelli F; Gallo A
    Neurol Sci; 2021 Feb; 42(2):731-733. PubMed ID: 33033898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fingolimod for multiple sclerosis: a review for the specialist nurse.
    Harrison K
    Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does fingolimod in multiple sclerosis patients cause macular edema?
    Turaka K; Bryan JS
    J Neurol; 2012 Feb; 259(2):386-8. PubMed ID: 22231867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
    Henault D; Galleguillos L; Moore C; Johnson T; Bar-Or A; Antel J
    Neurology; 2013 Nov; 81(20):1768-72. PubMed ID: 24132373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
    Aktas O; Ingwersen J; Kieseier B; Küry P; Hohlfeld R; Hartung HP
    Nervenarzt; 2011 Feb; 82(2):215-25. PubMed ID: 20842337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
    Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
    PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
    Camm J; Hla T; Bakshi R; Brinkmann V
    Am Heart J; 2014 Nov; 168(5):632-44. PubMed ID: 25440790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K; Adachi K
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
    Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.